Roger Perlmutter, Eikon CEO
January 6, 2022 07:00 AM ESTUpdated 12:45 PM
R&D

In new post-Mer­ck role, Roger Perl­mut­ter rakes in half a bil­lion dol­lars to change the way sci­en­tists look at pro­teins

Nicole DeFeudis

Editor

Roger Perl­mut­ter hasn’t wast­ed any time since an­nounc­ing his sup­posed re­tire­ment from Mer­ck in Oc­to­ber 2020. Af­ter leav­ing his perch as one of the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

A service from the Financial Times